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Abstract
CDKL5 mutation is associated with an atypical Rett syndrome (RTT) variant. Recently, 
cholesterol homeostasis perturbation and oxidative-mediated loss of the high-density lipoprotein 
receptor SRB1 in typical RTT have been suggested. Here, we demonstrate an altered lipid serum 
profile also in CDKL5 patients with decreased levels of SRB1 and impaired activation of the 
defensive system Nrf2. In addition, CDKL5 fibroblasts showed an increase in 4-hydroxy-2-
nonenal– and nitrotyrosine–SRB1 adducts that lead to its ubi-quitination and probable 
degradation. This study highlights a possible common denominator between two different RTT 
variants (MECP2 and CDKL5) and a possible common future therapeutic target.
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Mutations in loci other than the methyl-CpG binding protein 2 (MECP2) gene, linked to the 
occurrence of the typical Rett syndrome (RTT) [1–3], have been described in individuals 
labeled as atypical RTT. Although they have some overlapping clinical features of RTT, 
several variations in severity of impairment and clinical course have been described [4]. 
Among these variants, the “early-onset seizure variant,” initially described by Hanefeld in 
1985 [5], has been associated with mutations in the X-linked cyclin-dependent kinase-like 5 
(CDKL5) gene [6].
Approximately 100 CDKL5 cases were previously reported worldwide by the International 
Foundation for CDKL5 Research [7]. However, about 600 cases are known today to be 
present in the world [7], with a 1000% increase in the past 5 years, owing to the increase in 
familiarity of physicians and geneticists with CDKL5 mutations.
Recent evidence indicates that cholesterol homeostasis is perturbed in Mecp2-null mice 
owing to mutation in the gene encoding squalene epoxidase (SQLE), a rate-limiting 
cholesterol biosynthesis enzyme [8]. Moreover, our previous study demonstrated higher 
serum cholesterol in MECP2 patients (classical RTT), associated with an oxidative-mediated 
loss of scavenger receptor class B, type 1 (SRB1), a specific high-density lipoprotein (HDL) 
receptor [9], in fibroblasts isolated from MECP2 patients [10]. These new observations have 
brought new insights into possible therapeutic targets for RTT, although these aspects have 
not been evaluated for the other RTT variant CDKL5, which represents about 5% of RTT 
patients.
Recently, the presence of systemic redox imbalance has been described among the RTT 
variants [11] although the molecular mechanism responsible for increased oxidative stress 
(OS) was not elucidated. One of the main mechanisms involved in the cellular antioxidant 
defense is the activation of the nuclear factor erythroid 2-related factor 2 (Nrf2 or NFE2L2) 
system, a major transcription factor for antioxidant and cytoprotective responses [12–14]. 
Upon OS, Nrf2 translocates into the nucleus and binds to electrophile response elements 
(EpRE’s, also known as antioxidant response elements), increasing transcription of genes 
related to cellular defense [14]. Impaired Nrf2 activation has been suggested for several 
pathologies [15].
The present work was designed to evaluate the serum cholesterol profile in CDKL5 patients. 
Then, using freshly isolated skin fibroblasts, a good model to study the molecular 
mechanisms involved in several pathologies [16], we determined Nrf2 activation and the 
expression (protein and mRNA) and oxidative post-translational modification of SRB1.
1. Materials and methods
1.1. Subjects
Sixteen patients (females; mean age 11.4±5.1 years, range 2–18) with CDKL5 mutations 
were enrolled in this study. All the patients were consecutively admitted to the Rett 
Syndrome National Reference Center of the University Hospital of Siena (Azienda 
Ospedaliera Universitaria Senese). Thirty healthy control subjects were sex- and age-
matched (females; mean age 13.6±5.3 years, range 5–22). The subjects examined in this 
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study were on a typical Mediterranean diet. Blood samplings in the control group were 
carried out during routine health checks or blood donations, whereas blood samples from 
patients were obtained during periodic clinical checkups. The study was conducted with the 
approval of the institutional review board and all informed consents were obtained from 
either the parents or the legal guardians of the enrolled patients.
1.2. Determination of serum lipid profile
Fasting venous blood was collected at 8:00–10:00 AM after an overnight fast. Sera were 
separated and analyzed for total cholesterol (TC), triglycerides (TG), low-density lipoprotein 
cholesterol (LDL-C), and HDL-C, using specific diagnostic kits (HDL-cholesterol plus third 
generation and LDL-cholesterol plus second generation, respectively; Cobas, Roche, Basel, 
Switzerland).
1.3. Human dermal fibroblast culture
After informed consent, 4-mm punch biopsies were obtained from four CDKL5 patients and 
four healthy female control donors. Primary dermal fibroblasts were isolated from dermal 
tissue specimens, as previously described [10]. Fibroblasts at low passage were employed 
for the analyses.
1.4. Cell treatments and protein extraction
CDKL5 and healthy control fibroblasts (80–90% confluence) were seeded in 100-mm dishes 
and treated with 4-hydroxy-2-nonenal (HNE; 5 μM) or H2O2 (100 μM) for various times. 
Total, cytoplasmic, and nuclear extracts were obtained as previously described [17,18].
1.5. Immunoprecipitation
For immunoprecipitation, 500 μg of cellular protein was incubated with 5 μg of SRB1 
antibody (Millipore Corp., Billerica, MA, USA) and the assay was performed as previously 
described [10].
1.6. Western blotting
Protein concentrations were determined by the Bradford assay (Bio-Rad Laboratories, 
Segrate, Italy) and 40 μg of proteins was separated on 10% SDS–PAGE gels and transferred 
to nitrocellulose membranes. After blocking, the membranes were incubated with the 
primary antibodies: 4-hydroxy-2-nonenal, nitrotyrosine, SRB1 (Millipore), Nrf2 (Cell 
Signaling Technology, Danvers, MA, USA), and GCLC (gift from Professor H.J. Forman). 
After secondary antibody incubation, the membranes were exposed to enhanced 
chemiluminescence reagents and the bands visualized by autoradiography. Band 
densitometry was performed using ImageJ software. In some cases, membranes were 
stripped and reprobed with β-actin antibody (Millipore). Results were normalized with the 
respective loading control (Ponceau or β-actin).
1.7. Immunofluorescence
Healthy control and CDKL5 fibroblasts were seeded on cover-slips at a density of 2 ×104 
cells/cm2. For Nrf2 nuclear translocation, fibroblasts were treated for 1 h with H2O2 (100 
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μM) or HNE (5 μM). After fixation and blocking, the cells were incubated overnight with 
the primary antibodies: 4-hydroxy-2-nonenal, nitrotyrosine, SRB1 (Millipore), and Nrf2 
(Cell Signaling Technology). Then, the cells were incubated with Alexa Fluor 568 and Alexa 
Fluor 488 antibodies (Life Technologies Italia, Monza, Italy). The nuclei were stained with 
DAPI. Negative controls were generated by omitting the primary antibodies. Images were 
acquired with a Leica AF CTR6500HS microscope (Microsystems). For automatic 
visualization of colocalized fluorescence signals, ImageJ software was used, and the 
threshold values were determined and set for the two channels, so as to eliminate 
background noise. White spots represent positive correlation (colocalization).
1.8. Reverse transcription quantitative real-time PCR
Total RNA was extracted from fibroblasts using the RNeasy mini kit (Qiagen, Hilden, 
Germany) and RT-qPCR was performed as previously reported [19]. Primer sequences were 
SRB1, fwd 5′-GAATTCGCCTTTCGTCCCCG-3′, rev 5′-
TTGAAGGACAGGCTACTGGG-3′; GCLC, fwd 5′-ACAGGACCAACCGGACTTTT-3′, 
rev 5′-CAGACTTC ACGTTTCCCTGC-3′; and GAPDH (internal standard), fwd 5′-TGAC 
GCTGGGGCTGGCATTG-3′, rev 5′-GGCTGGTGGTCCAGGGGTCT-3′. After 
normalization to more stable GAPDH mRNA, the folds of variation were determined with 
respect to the control, using the formula 2−ΔΔCt, where ΔCt is (gene of interest Ct) − 
(GAPDH Ct) and ΔΔCt is (ΔCt experimental) − (ΔCt control).
1.9. Oil red O staining
Fibroblasts were seeded on coverslips and incubated with 50 μg/ml HDL for 24 h and then 
fixed for 30 min at room temperature with 4% paraformaldehyde. Fixed cells were stained 
with freshly prepared oil red O solution for 30 min at 60 °C. The nuclei were stained with 
hematoxylin for 5 min. Images were acquired with a Leica AF CTR6500HS microscope 
(Microsystems). To quantify staining, oil red O was extracted from cells and the absorbance 
was then measured at 492 nm. Cell protein concentrations were determined and absorbance 
values were normalized to protein.
1.10. Statistical analysis
Results are expressed as means±SD. Statistical comparisons were performed using the 
Student t tests. A P value of <0.05 was considered statistically significant.
2. Results
2.1. Serum lipid profile alteration in CDKL5 patients
As shown in Table 1, CDKL5 patients present an altered lipid profile. Indeed, TC 
(194.6±24.7 mg/dl), LDL-C (103.5±16.4 mg/dl), and HDL-C (67.9±17.9 mg/dl) levels in 
CDKL5 patients were significantly higher than in the control group (162.3±14.6, 87.6±11.3, 
49.8±6.3 mg/dl, respectively; P<0.05). However, TG levels, although higher in the CDKL5 
group (88.9±33.8 mg/dl), were not significantly different from controls (80.2±20.2 mg/dl).
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2.2. CDKL5 fibroblasts present low levels of SRB1 protein
The alterations in the serum lipid profile observed in CDKL5 patients prompted us to 
analyze the SRB1 protein level, given its critical role in lipoprotein metabolism and 
cholesterol homeostasis [9]. As shown in Fig. 1A, in CDKL5 fibroblasts we observed a 
significant decrease in SRB1 protein level (about 37%) compared to control cells.
2.3. Upregulation of SRB1 mRNA expression in CDKL5 fibroblasts
To explore the possible mechanism by which SRB1 is down-regulated in CDKL5 
fibroblasts, the transcription level of SRB1 was analyzed. As shown in Fig. 1B, SRB1 
mRNA levels were significantly increased (about sixfold) in CDKL5 cells compared to the 
control cells.
2.4. Increased oxidative marker levels in CDKL5 fibroblasts
One mechanism that can lead to the loss of proteins is oxidative modification, which can 
mark them for degradation [20,21]. Therefore we analyzed the presence of oxidative 
markers in CDKL5 fibroblasts. As is shown in Fig. 2, immunoblotting analysis revealed 
several reactive bands for HNE–protein adducts (HNE–PA; Fig. 2A, left) and nitrotyrosine 
protein adducts (NT–PA; Fig. 2A, right) in CDKL5 cell lysates, whereas fewer and/or 
weaker bands were observed in control cells. Oxidatively modified proteins were detected in 
both the high and the lower molecular weight bands, but showed a stronger intensity 
between 50 and 250 kDa for HNE–PA (Fig. 2A, left) and between 50 and 100 kDa for NT–
PA (Fig. 2A, right). Densitometry analysis of all the bands present in each lane showed a 
significant increase in both HNE–PA and NT–PA levels in CDKL5 fibroblasts (Fig. 2A, 
bottom). Data were also confirmed by immunofluorescence (Fig. 2B).
2.5. Inducible nitric oxide synthase upregulation in CDKL5 fibroblasts
To understand the source of NT–PA, we assessed the expression of inducible nitric oxide 
synthase (iNOS) protein. As shown in Fig. 2C, CDKL5 fibroblasts had a markedly increased 
expression of iNOS (threefold).
2.6. SRB1 oxidative posttranslational modifications affect cholesterol uptake in CDKL5 
fibroblasts
After confirming the evidence of cellular nitrosative/oxidative imbalance with increased 
oxidative posttranslational modifications in CDKL5 patients, we examined whether SRB1 
can form adducts with HNE and NT. As evident from Fig. 3A (top), immunoprecipitation/
Western blotting assays revealed the heightened occurrence of HNE– and NT–SRB1 adducts 
in CDKL5 fibroblasts, also confirmed by double immunofluorescence (Fig. 3A, bottom). In 
particular, green fluorescence for SRB1 confirmed its lower levels in CDKL5 cells (left 
column) with an associated increase in HNE–PA levels (central column, red fluorescence). A 
clear colocalization of SRB1 with HNE–PA was evident in the merged images (right 
columns, yellow color and white spots), indicating the formation of HNE–SRB1 adducts in 
CDKL5 fibroblasts.
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In addition, we evaluated whether the ubiquitination process was involved in the 
posttranslational modifications of SRB1. As shown in Fig. 3B, immunoprecipitation assays 
show a clear interaction between ubiquitin and SRB1, data confirmed also by 
immunofluorescence (Fig. 3B, bottom). Merged images (yellow color) show the association 
of SRB1 and ubiquitin; in particular the areas of colocalization, indicated by white spots, 
clearly demonstrated more overlap of the two signals in CDKL5 fibroblasts.
The cellular ability to take up HDL-C was determined in control and CDKL5 cells. As 
shown in Fig. 3C, CDKL5 cells showed an impaired ability to take up cholesterol (lipid 
droplets in red) with respect to the control cells. This difference was statistically significant, 
as quantified on the left (Fig. 3C).
2.7. Aberrant Nrf2 activation in CDKL5 fibroblasts
As the stability and nuclear translocation of the transcription factor Nrf2 increase in 
response to OS and are critical in the regulation of intracellular redox balance [12–14], we 
examined Nrf2 protein levels and translocation. As shown in Fig. 4A, in CDKL5 fibroblasts 
Nrf2 protein expression was 56% lower than in control cells. In addition, we evaluated the 
cytoplasmic (data not shown) and nuclear levels of Nrf2 in control and CDKL5 cells after 
challenging them for 1 h with two well-known Nrf2 activators, i.e., H2O2 and HNE. As 
shown in Fig. 4B, CDKL5 cells had lower nuclear levels of Nrf2 and were not able to further 
induce Nrf2 translocation after H2O2 or HNE exposure. Instead, control cells showed a clear 
ability to induce Nrf2 translocation after the different stimulations (Fig. 4B).
The data were also confirmed by immunofluorescence, as shown in Fig. 4C; control cells 
exhibited higher levels of both cytoplasmic and nuclear Nrf2 than did CDKL5 cells. 
Furthermore, when the cells were challenged with H2O2 or HNE, CDKL5 showed a clearly 
lower response in terms of Nrf2 activation.
The aberrant activation of Nrf2 was further confirmed by analyzing the expression (mRNA 
and protein) of GCLC, a gene regulated by Nrf2 [22]. As is depicted in Fig. 5A, CDKL5 
cells showed a lower level of GCLC mRNA and treatment with HNE did not affect its 
expression after 12 h. This effect was also noticed for GCLC protein levels, as shown in Fig. 
5B. Control cells were able to increase both mRNA and protein levels of GCLC after the 
challenge with HNE (Fig. 5A and 5B).
3. Discussion
Mutations in CDKL5, a gene located on the X chromosome and encoding cyclin-dependent-
like kinase 5, have been identified in individuals with an atypical variant of RTT, a severe 
neurologic disorder linked to mutations in the X-linked MECP2 gene [1–6]. CDKL5 patients 
show early-onset intractable seizures and a wide variety of other symptoms, such as 
neurodevelopmental impairment, intellectual disability, and motor delay [23].
Evidence indicates that CDKL5 binds to and phosphorylates MeCP2 in vitro, suggesting a 
possible molecular link between CDKL5 disorder and typical RTT [24]. Therefore, some 
similarities between typical RTT and CDKL5 are related not only to the clinical features, but 
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also to the cellular and molecular mechanisms. For instance, a recent study has shown that 
neurons with CDKL5 mutation and neurons with MECP2 mutation have a common altered 
gene, GluD1, which is involved in neuronal differentiation [25].
In the present work, we have demonstrated that the loss of SRB1 and the altered serum lipid 
profile previously noticed in MECP2 patients [10] are present also in CDKL5 subjects. 
Because of their strictly controlled diet, this increase in serum cholesterol levels should be 
the consequence of an altered lipid metabolism linked to the diseases.
In addition, cholesterol has multiple roles in the nervous system, from membrane trafficking 
to myelin formation, along with synapsis formation [26]. Therefore, the understanding of 
cholesterol metabolism has become an emerging area in several neurological diseases.
In fact, very recently, in an elegant study published in Nature Genetics, Buchovecky and 
colleagues [8] showed that cholesterol metabolism is perturbed in the brain and liver of 
Mecp2-null male mice, suggesting that cholesterol homeostasis maintenance could be 
disrupted in RTT and deeply involved in the onset of the disease. In addition, in a recent 
work we have also shown that 3-hydroxy-3-methylglutaryl-CoA reductase, the rate-limiting 
enzyme of the cholesterol biosynthetic pathway [27,28], was significantly lower in 
fibroblasts isolated from RTT patients [29], confirming not only the “cholesterol pathway” 
aberration, but also the reliability of the model used (skin fibroblasts isolated by biopsy). 
Indeed, in the present work we have found a significant increase in HDL and LDL levels in 
CDKL5 patients and this was associated with loss of SRB1. In fact, SRB1 is involved in the 
binding of HDL and also LDL, thereby promoting selective tissue uptake of cholesterol [9]. 
In addition, SRB1 is also implicated in several other cellular processes, such as recognition 
of pathogens and apoptotic cells as well as uptake of lipid-soluble antioxidants [9], all 
features found altered in RTT. SRB1 can be modulated by either exogenous or endogenous 
OS [9] and the presence of chronic OS has been well documented in CDKL5 with a strong 
correlation between the levels of OS markers and disease severity [11]. We suggest that the 
loss of SRB1 is most likely due to the oxidative posttranslational modifications observed as 
HNE adducts and NT modification of SRB1. The discrepancy between mRNA and protein 
expression of SRB1 in CDKL5 fibroblasts leads us to conclude that the loss of protein is not 
at the transcriptional level, but can be the consequence of posttranscriptional events. Thus, 
the upregulation of SRB1 mRNA may represent an attempted compensatory mechanism for 
the increased protein turnover (positive feedback). It should also be mentioned that elevated 
mRNA levels of proteins that have been damaged by oxidative stress could also depend on 
an altered translation process by affecting ribosomal proteins and leading to protein 
misfolding. Indeed, when cells are exposed to OS, several targets can be oxidized and many 
metabolic pathways, such as translation, can be corrupted [30]. For instance, it has been 
demonstrated that OS is able to inactivate several enzymes involved in the metabolism of 
energy and amino acid synthesis [31], which are involved in protein synthesis. Furthermore, 
several players that participate in translation have been found to be targets of oxidation, 
including elongation factors, ribosomal proteins, tRNA, and aminoacyl-tRNA synthetases 
[32]. We do not exclude that some of these pathways also contribute to the detected 
discrepancy between SRB1 mRNA and protein levels.
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In fact, we have previously shown that SRB1 is susceptible to HNE adducts and this leads to 
its ubiquitination and then to its degradation via the proteasomal machinery [10,33], and this 
is in line with the data presented in this work. In addition, our results are in line with our 
previous work showing increased HNE–PA plasma levels in CDKL5 patients [11].
We should also mention that SRB1 can be regulated at the transcriptional level by several 
factors (LXRs, SREBP, PPAR, miRNAs, etc.), which could also be involved in our system 
although there are no data in the literature on the possible SRB1 transcriptional regulation in 
RTT.
Several defensive pathways can be activated by cells against OS. Among these, there is the 
activation of the redox-sensitive transcription factor Nrf2, able to regulate the expression of 
many “antioxidant” genes and other cytoprotective phase II detoxifying enzymes through 
binding to EpRE’s [12–14]. Moreover, recent work has also demonstrated that Nrf2 can be 
involved in the regulation of proteasome subunits [34]. In addition, it has also been reported 
that proteasome inhibitors can protect cells and tissues against oxidative damage, because 
they can activate the Nrf2 pathway [35–37]. In line with the above-mentioned studies, our 
data showed that Nrf2 translocation in CDKL5 cells was significantly lower than in the 
control, once challenged with H2O2 or HNE, suggesting the inability of CDKL5 cells to 
induce a proper defensive response, as also demonstrated by the GCLC data. Moreover, it is 
likely that CDKL5 cells exhibit an impaired protein degradation/turnover, resulting in 
increased accumulation of oxidatively modified proteins.
In addition, Nrf2 is also a regulator of the aldo-keto reductase AKR1C1 [38]. AKR1C1-
mediated reduction of HNE has been reported in human hepatoma HepG2 cells and 
astrocytes [39,40]. Therefore, AKR1C1 is involved in the protection of cells against HNE 
toxicity and it is logical to suppose that the lower level of Nrf2 in CDKL5 cells is also 
responsible for the inability to prevent deleterious effects of HNE. Furthermore, the 
increased levels of NT can be explained by the induction of iNOS and these results are in 
line with a recent study that demonstrated the increase in NT levels in Nrf2-knockout mice 
[41]. HNE, in a dose-dependent manner, is also able to induce NO production, as suggested 
by Gatbonton-Schwager et al., through cross talk between iNOS and Nrf2 [42]. The lower 
activation of Nrf2 in CDKL5 could be a consequence of the high levels of HNE, as 
demonstrated for another redox-sensitive transcription factor, NF-κB. Studies have shown 
that low concentrations of HNE (~1 μM) can promote IκB-α phosphorylation, leading to 
NF-κB activation [43,44]. In contrast, higher concentrations of HNE (5–50 μM) inhibit IκB-
α degradation via the proteasome [43,45].
In conclusion, the present work demonstrated a close similarity between typical RTT and 
CDKL5 disorder in terms of serum cholesterol levels and SRB1 posttranslational 
modifications. The loss of SRB1 can be associated with increased lipoproteins found in the 
serum of CDKL5 patients and may be the consequence of increased levels of HNE and 
ubiquitin adducts. This is the first report showing in CDKL5 patients an increase in both 
oxidative and nitrosative stress markers and a Nrf2 aberrant activation, all factors that can 
contribute to cell damage (Scheme 1).
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This work demonstrates a novel mechanism in CDKL5 pathology and a common 
denominator between two RTT variants, suggesting new insights for possible therapeutic 
targets that may contribute to improving the quality of life for these patients.
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Fig. 1. 
SRB1 protein and mRNA expression in CDKL5 fibroblasts. (A) Top, a representative 
Western blot of SRB1 in healthy control (n=4) and CDKL5 (n=4) fibroblasts is shown. 
Bottom, the relative SRB1 levels normalized to a Ponceau-stained band around 40 kDa. 
Values are reported as arbitrary units. Data are means±SD of three separate experiments. 
*P<0.05. (B) The relative levels of SRB1 mRNA expression in healthy control (n=4) and 
CDKL5 (n=4) fibroblasts, as quantified by RT-qPCR. Data are the means±SEM of three 
independent experiments, each analyzed in triplicate. The SRB1 mRNA is normalized to 
GAPDH and expressed as a fold change. *P<0.05.
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Fig. 2. 
CDKL5 fibroblasts show increased oxidative stress markers, i.e., 4-hydroxy-2-nonenal–
protein adducts, nitrotyrosine–protein adducts, and overexpression of iNOS. (A) 
Representative Western blots for HNE–PA (left) and NT–PA (right) in healthy control (n=4) 
and CDKL5 (n=4) fibroblasts are shown. HNE–PA were present between 50 and 250 kDa, 
and bands reactive for NT–PA were observed in the range of 50 to 100 kDa. At the bottom is 
presented the Western blot quantification. (B) Immunofluorescence for HNE–PA (red) and 
NT–PA (green) in control and CDKL5 fibroblasts. Original magnification, ×630. Scale bar, 
50 μm, valid for all images. (C) Left, a representative Western blot of iNOS protein levels in 
healthy control (n=4) and CDKL5 (n=4) fibroblasts. Right, quantification of the iNOS 
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Western blot. Values are reported as arbitrary units. Data are means±SD of at least three 
independent experiments. *P<0.05.
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Fig. 3. 
SRB1 posttranslational modifications and cholesterol uptake in CDKL5 fibroblasts. (A) 
Representative immunoblotting of HNE and NT for immunoprecipitated SRB1 in control 
(n=4) and CDKL5 (n=4) fibroblasts (top). Bottom, double immunofluorescence shows the 
presence of SRB1 (green fluorescence), HNE–PA (red fluorescence), and HNE–SRB1 
adducts (yellow) in healthy control and CDKL5 fibroblasts. In the merged images, white 
spots indicate the clear colocalization of SRB1 with HNE in CDKL5 fibroblasts. Original 
magnification, ×630. Scale bar, 50 μm. (B) Representative immunoblotting of ubiquitin after 
SRB1 immunoprecipitation. Control (n=4) and CDKL5 (n=4) fibroblasts (top). Bottom, 
double immunofluorescence shows the presence of SRB1 (green fluorescence), ubiquitin 
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(red fluorescence), and ubiquitin–SRB1 adducts (yellow) in healthy control and CDKL5 
fibroblasts. In the merged images, white spots indicate the clear colocalization of SRB1 with 
ubiquitin in CDKL5 fibroblasts. Original magnification, ×630. Scale bar, 50 μm. (C) 
Representative images of oil red O staining show a reduced number of cellular lipid droplets 
in CDKL5 fibroblasts exposed to HDL (50 μM) for 24 h (left). Original magnification, 
×1000. Scale bars, 10 μm. Right, histogram shows quantification of HDL-cholesterol uptake. 
Values are reported as optical density at 492 nm, normalized to protein concentration. Data 
are means±SD of three separate experiments. aP<0.05 between treated and not treated 
samples; bP<0.05 between control and CDKL5 treated samples.
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Fig. 4. 
Levels and nuclear translocation of Nrf2. (A) Top, representative Western blot for Nrf2 in 
healthy control (n=4) and CDKL5 (n=4) fibroblasts. Bottom, the Western blot quantification. 
Values are reported as arbitrary units. Data are means±SD of at least three separate 
experiments. *P<0.05. (B) Representative Western blot for Nrf2 nuclear translocation in 
healthy control (n=4) and CDKL5 (n=4) fibroblasts challenged with H2O2 (left) or HNE 
(right) at various time points. Bottom, quantification of Nrf2 nuclear levels relative to lamin 
C. Values are reported as arbitrary units. Data are means±SD from three separate 
experiments. aP<0.05 in the same group; bP<0.05 between control and CDKL5. (C) 
Representative images of immunofluorescence for Nrf2 nuclear translocation in healthy 
control and CDKL5 fibroblasts treated with H2O2 (left) or HNE (right) for 1 h. Original 
magnification, ×630. Scale bar, 50 μm, valid for all images.
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Fig. 5. 
GCLC mRNA and protein levels in CDKL5 and healthy fibroblasts. (A) Basal and HNE-
stimulated levels of GCLC mRNA expression in healthy control (n=4) and CDKL5 (n=4) 
fibroblasts. Data are the means±SEM of three independent experiments, each analyzed in 
triplicate. The GCLC mRNA is normalized to GAPDH and expressed as a fold 
change. aP<0.05 in the same group; bP<0.05 between control and CDKL5 treated samples. 
(B) Representative Western blot for GCLC protein levels in healthy control (n=4) and 
CDKL5 (n=4) fibroblasts challenged with HNE for 12 h. Bottom, the Western blot 
quantification. The values are reported as arbitrary units. Data are means±SD of three 
separate experiments. aP<0.05 in the same group; bP<0.05 between control and CDKL5 
treated samples.
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Scheme 1. 
Several mechanisms can play a role in CDKL5 disorder, such as redox imbalance and 
altered cholesterol pathway, two possible common denominators between typical RTT and 
CDKL5 patients. Owing to a possible Nrf2 aberrant activation with a defective expression of 
Nrf2 target genes (detoxifying enzymes, etc.), in CDKL5 cells the redox imbalance can 
contribute to the loss of SRB1 as a consequence of increased oxidative modifications and 
ubiquitin adduct formation in SRB1 protein. In addition, the decrease in SRB1 levels is 
associated with the reduction in intracellular lipid uptake and the increase in serum 
lipoproteins found in CDKL5 patients. Finally, a possible positive feedback loop can be the 
cause of the SRB1 mRNA overexpression. ARE, antioxidant-response element.
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Table 1
Comparison of serum lipid profiles between healthy normal controls and CDKL5 patients.
Healthy controls CDKL5 patients Student’s t test P value
TC (mg/dl) 162.3±14.6 194.6±24.7 0.00001
TG (mg/dl) 80.2±20.2 88.9±33.8 0.32674
LDL-C (mg/dl) 87.6±11.3 103.5±16.4 0.04037
HDL-C (mg/dl) 49.8±6.3 67.9±17.9 0.00303
Total number 30 16 —
The values are expressed as means±SD. Abbreviations: TC, total cholesterol; TG, triglycerides; LDL-C, low-density lipoprotein cholesterol; HDL-
C, high-density lipoprotein cholesterol.
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